The 5-HT3 receptor antagonist, RS-56812, enhances delayed matching performance in monkeys

NeuroReport

Volumn 8, Issue 1, 1997, Pages 49-54

  Terry Jr , Alvin V ^a,b   Buccafusco, Jerry J ^a,b   Prendergast, Mark A ^a   Jackson, William J ^a   Fontana, David L ^c   Wong, Erik H F ^c   Whiting, Roger L ^c   Eglen, Richard M ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Inst Pharmacol Neurbio Roche B   (United States)

Author keywords

5HT3 receptors; Acetylcholine; Matching to sample; Memory; Monkey; Receptors; Serotonin

Indexed keywords

PLACEBO; RS 56812; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; QUINUCLIDINE DERIVATIVE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ENANTIOMER; FEMALE; HUMAN; MALE; MEMORY; MONKEY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ANIMAL; COLOR VISION; DOSE RESPONSE; DRUG EFFECT; ISOMERISM; MACACA; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; STIMULATION;

ANIMALS; COLOR PERCEPTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; ISOMERISM; MACACA FASCICULARIS; MACACA NEMESTRINA; MALE; MEMORY; PSYCHOMOTOR PERFORMANCE; QUINUCLIDINES; SEROTONIN ANTAGONISTS; STIMULATION, CHEMICAL;

EID: 0030595870     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199612200-00011     Document Type: Article

References (25)

1. McEntee WJ and Crook TH. Psychopharmacology 103, 143-149 (1991).
2. Maura G and Raiteri M. Eur J Pharmacol 129, 333-337 (1986).
3. Kilpatrick GJ, Jones BJ and Tyers MB. Nature 330, 746-768 (1987).
4. Waeber C, Hoyer D and Palacios JM. Neuroscience 31, 393-400 (1989).
5. Barnes JM, Barnes NM, Costall B et al. Nature 338, 762-763 (1989).
6. Maura G, Andrioli GC, Cavazzani P et al. J Neurochem 58, 2334-2337 (1992).
7. Altman HJ and Normile HJ. Psychopharmacology 90, 24-27 (1986).
8. Altman HJ and Normile HJ. Pharmacol Biochem Behav 28, 353-359 (1987).
9. Strek KF, Spencer KR and DeNoble VJ. Pharmacol Biochem Behav 33, 241-244 (1989).
10. DeNoble VJ, Schrack LM, Reigel AL et al. Pharmacol Biochem Behav 39, 91-996 (1991).
11. Barnes JM, Costall B, Coughlan J et al. Pharmacol Biochem Behav 35, 955-962 (1990).
12. Domeney AM, Costall B, Gerrard PA et al. Pharmacol Biochem Behav 38, 169-175 (1991).
13. Fontana DJ, Daniels SE, Henderson C et al. Psychopharmacology 120, 409-417 (1995).
14. Carey GJ, Costall B, Domeney AM et al. Pharmacol Biochem Behav 42, 75-83 (1992).
15. Pitsikas N, Brambilla A and Borsini F. Neurobiol Aging 14, 561-564 (1994).
16. Broekkamp CL, Garrigou D and Lloyd KG. Pharmacol Biochem Behav 13, 643-646 (1980).
17. Lorden JF, Rickert EJ and Berry DW. J Pharmacol Exp Ther 247, 1120-1127 (1983).
18. Solomon PR, Nichols GL, Kiernan JM et al. J Comp Physiol Psychol 94, 145-154 (1980).
19. Clark RD, Muchowski JM, Weinhardt KK et al. Bioorg Med Chem Lett 5, 1853-1856 (1995).
20. Buccafusco JJ, and Jackson WJ. Neurobiol Aging 12, 233-238 (1991).
21. Terry AV, Buccafusco JJ and Jackson WJ. Pharmacol Biochem Behav 45, 925-929 (1993).
22. Chugh Y, Saha N, Sankaranarayanan A et al. Pharmacol Toxicol 69, 105-106 (1991).
23. Chugh Y, Saha N, Sankaranarayanan A et al. Eur J Pharmacol 203, 121-123 (1991).
24. Terry AV, Jackson WJ and Buccafusco JJ. Cerebr Cortex 3, 304-312 (1993).
25. Irle E, Kessler J and Markowitsch HJ. Brain Cogn 6, 429-449 (1987).